About BTPA

We are a non-profit organisation run by Bowen Therapists for Bowen Therapists. We outline standards that need to be met by members to work professionally within new legislastion and regulations.

Wednesday 1 February 2012

Concerns over new ‘medical marijuana’ drug

The new ‘medical marijuana’ drug on the market has sparked concern for possible addiction in patients using it to get ‘high’ rather than treating their pain.



‘Sativex’ is being trialed by pharmaceutical company GW Pharmaceuticals, which will be delivered as a mouth spray. The drug will be seeking approval from the U.S FDA to be used as a treatment for cancer pain. 



The active ingredients in Sativex, known as cannabinoids, are derived from the cannabis plant. It is the first marijuana-based drug to be made by extracting the compounds from the plant, rather than synthesizing them.

Because the drug contains THC, the ingredient primarily responsible for marijuana's "high," its possible people would use the drug for recreational rather than medical purposes.

"There is no doubt in my mind that there will be people that abuse it," said Dr. Jeffrey Bernstein, director of the Florida Poison Information Center at the University of Miami Miller School of Medicine.

The drug is already approved in United Kingdom, Spain, Canada and New Zealand to treat muscle spasms due to multiple sclerosis, according to the company website.

However an alternative treatment for the pain of multiple sclerosis is the Bowen Technique with many sufferers finding more flexible movement in their limbs and improved mobility.


The Bowen Technique helps the body remember how to heal itself. The gentle yet powerful Bowen moves send neurological impulses to the brain resulting in immediate responses of muscle relaxation and pain reduction, which is excellent for those suffering with multiple sclerosis.  

No comments:

Post a Comment